Miami Shores, Florida Clinical Trials
A listing of Miami Shores, Florida clinical trials actively recruiting patient volunteers.
Found 57 clinical trials
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa (HS) in adult participants with moderate to severe disease. …
- 0 views
- 19 Feb, 2024
- +27 other locations
Assessment of the Efficacy Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- 0 views
- 19 Feb, 2024
- +1 other locations
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.
- 0 views
- 19 Feb, 2024
- +155 other locations
![ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection](/media/imagery/3815.svg)
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
This trial will evaluate the safety, efficacy, pharmacokinetics, fecal concentrations, and fecal microbiome effects of ACX-362E [ibezapolstat] in patients with C. difficile infection (CDI). The current record applies only to Segment 2A, primary completion date August 2020.
- 0 views
- 19 Feb, 2024
- +5 other locations
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
This is a Phase 1, open-label, parallel design, single-dose pharmacokinetic (PK) study to assess the safety, tolerability, and PK of a single dose of 50 mg of DS-3201b in participants with normal and impaired hepatic function.
- 0 views
- 19 Feb, 2024
- +2 other locations
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp). …
- 0 views
- 19 Feb, 2024
- +6 other locations
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
- 0 views
- 19 Feb, 2024
- +18 other locations
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab
This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …
- 0 views
- 19 Feb, 2024
- +30 other locations
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.The study consists of 3 periods:Screening period: 2 to 4 weeks.Treatment period: 24 weeks.Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods).The total number of planned …
- 0 views
- 14 May, 2025
- +5 other locations
A Study Evaluating JUV DERM VOLUMA XC Injectable Gel for Correction of Temple Hollowing in Adult Participants Over 22 Years Old
The objectives of this study are to evaluate the safety and effectiveness of Juvederm Voluma XC injectable gel in adult participants seeking correction of temple hollowing
- 0 views
- 19 Feb, 2024
- +14 other locations